Viewing atherosclerosis through a crystal lens: How the evolving structure of cholesterol crystals in atherosclerotic plaque alters its stability

• Published in: Journal of clinical lipidology Vol. 14; no. 5; pp. 619 - 630
• Main Authors: Nidorf, Stefan Mark, Fiolet, Aernoud, Abela, George S.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-09-2020
• Subjects: Acute coronary syndromes; Atherosclerosis; Lipids and cholesterol; Acute coronary syndromes; Lipids and cholesterol; Atherosclerosis
• ISSN: 1933-2874; 1876-4789
• DOI: 10.1016/j.jacl.2020.07.003

Reducing the residual risk of cardiovascular (CV) events in patients with atherosclerosis continues to be a challenge. Thus, understanding how cholesterol spontaneously self assembles into metastable structures that evolve into flat plate cholesterol crystals (CCs) in atherosclerotic plaque, and why they fundamentally change the nature of the disease provides a paradigm for the development of additional therapies. Specifically, flat plate CCs that form within lysosomes of macrophages may become large enough to disrupt lysosomal membranes leading to the release of cathepsin B and CCs fragments directly into the cytosol. In the cytosol, the surface of flat plate CCs can be recognized by complosome that together with cathepsin B may trigger pyrin domain-containing inflammasome. In addition, flat plate CCs in the cytosol may trigger caspase 8 initiating apoptosis. In the interstitial space, the surface of flat plate CCs can be recognized by complement and receptors on proinflammatory cells, and larger fragments can induce “frustrated phagocytosis” that together perpetuate inflammatory injury. In addition, rapid transition of metastable CCs into large flat plate CCs within lipid rich plaques can lead to traumatic injury by expansion of the plaque's necrotic core causing plaque disruption or rupture that may precipitate further inflammation. Other crystalloids in plaque including monosodium urate and calcium phosphate crystals can augment these processes. Thus, therapies that further limit the deposition of cholesterol in the vascular bed, slow the formation of flat plate CCs and inhibit crystal-induced inflammation may lead to further reduce CV risk in patients with established CV disease.
•Reducing vascular risk in patients with atherosclerosis is an ongoing challenge.•Understanding how cholesterol causes atherosclerosis provides rationale for therapy.•Free cholesterol may form metastable structures that evolve into flat plate cholesterol crystals (CCs).•Free flat plate CCs persist and predispose to inflammatory and traumatic injury.•Inhibiting CCs growth and crystal-induced inflammation may reduce vascular risk.